Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pituitary ACTH Hypersecretion | 39 | 2024 | 178 | 12.050 |
Why?
|
Human Growth Hormone | 68 | 2022 | 637 | 10.720 |
Why?
|
Cushing Syndrome | 35 | 2024 | 242 | 7.520 |
Why?
|
Acromegaly | 23 | 2020 | 306 | 3.790 |
Why?
|
Somatostatin | 19 | 2022 | 447 | 3.440 |
Why?
|
Hormone Replacement Therapy | 20 | 2021 | 755 | 3.120 |
Why?
|
Hydrocortisone | 40 | 2024 | 1796 | 2.980 |
Why?
|
Hypopituitarism | 17 | 2019 | 248 | 2.950 |
Why?
|
Dwarfism, Pituitary | 9 | 2022 | 39 | 2.550 |
Why?
|
Pituitary Neoplasms | 31 | 2023 | 1312 | 1.800 |
Why?
|
Adenoma | 21 | 2022 | 2145 | 1.700 |
Why?
|
Growth Hormone | 20 | 2022 | 568 | 1.650 |
Why?
|
Receptors, Somatotropin | 5 | 2020 | 58 | 1.610 |
Why?
|
Insulin-Like Growth Factor I | 35 | 2022 | 1919 | 1.490 |
Why?
|
Ketoconazole | 6 | 2021 | 97 | 1.450 |
Why?
|
Adrenocorticotropic Hormone | 20 | 2019 | 619 | 1.440 |
Why?
|
ACTH-Secreting Pituitary Adenoma | 5 | 2020 | 63 | 1.440 |
Why?
|
Dopamine Agonists | 10 | 2023 | 352 | 1.430 |
Why?
|
Adrenal Insufficiency | 10 | 2022 | 192 | 1.370 |
Why?
|
Hyperprolactinemia | 10 | 2023 | 123 | 1.330 |
Why?
|
Hormones | 7 | 2020 | 867 | 1.250 |
Why?
|
Pituitary Gland | 7 | 2021 | 637 | 1.080 |
Why?
|
Glucagon | 6 | 2016 | 531 | 1.040 |
Why?
|
Receptors, Glucocorticoid | 3 | 2018 | 296 | 1.000 |
Why?
|
Mifepristone | 6 | 2020 | 150 | 0.990 |
Why?
|
Endocrinology | 6 | 2020 | 442 | 0.950 |
Why?
|
Diagnostic Techniques, Endocrine | 3 | 2012 | 43 | 0.900 |
Why?
|
Hormone Antagonists | 6 | 2017 | 108 | 0.890 |
Why?
|
Imidazoles | 7 | 2024 | 1175 | 0.850 |
Why?
|
Quality of Life | 21 | 2024 | 13285 | 0.770 |
Why?
|
Bone Density | 14 | 2017 | 3517 | 0.750 |
Why?
|
Body Composition | 17 | 2020 | 2414 | 0.710 |
Why?
|
Arginine | 7 | 2020 | 934 | 0.650 |
Why?
|
Petrosal Sinus Sampling | 3 | 2012 | 22 | 0.650 |
Why?
|
Pituitary-Adrenal System | 5 | 2016 | 550 | 0.630 |
Why?
|
Adult | 132 | 2024 | 219353 | 0.600 |
Why?
|
Hypothalamo-Hypophyseal System | 5 | 2016 | 699 | 0.590 |
Why?
|
Antimetabolites | 1 | 2018 | 127 | 0.590 |
Why?
|
Circadian Rhythm | 5 | 2020 | 2567 | 0.580 |
Why?
|
Prolactinoma | 5 | 2023 | 113 | 0.560 |
Why?
|
Corticotropin-Releasing Hormone | 7 | 2012 | 361 | 0.560 |
Why?
|
Recombinant Proteins | 8 | 2020 | 6538 | 0.550 |
Why?
|
Pyridines | 6 | 2024 | 2876 | 0.540 |
Why?
|
Mitotane | 4 | 2020 | 19 | 0.530 |
Why?
|
Cranial Irradiation | 2 | 2017 | 391 | 0.520 |
Why?
|
Treatment Outcome | 36 | 2024 | 64867 | 0.510 |
Why?
|
Metyrapone | 4 | 2019 | 23 | 0.500 |
Why?
|
Humans | 185 | 2024 | 759098 | 0.470 |
Why?
|
Saliva | 7 | 2020 | 816 | 0.470 |
Why?
|
Steroid 11-beta-Hydroxylase | 1 | 2013 | 20 | 0.460 |
Why?
|
Neurotransmitter Agents | 1 | 2018 | 661 | 0.460 |
Why?
|
Middle Aged | 97 | 2024 | 219628 | 0.450 |
Why?
|
Radiosurgery | 6 | 2017 | 1341 | 0.440 |
Why?
|
Female | 120 | 2024 | 390174 | 0.440 |
Why?
|
Ergolines | 5 | 2017 | 57 | 0.440 |
Why?
|
Growth Disorders | 5 | 2019 | 651 | 0.400 |
Why?
|
Enzyme Inhibitors | 4 | 2022 | 3722 | 0.400 |
Why?
|
Prolactin | 8 | 2023 | 621 | 0.390 |
Why?
|
Male | 101 | 2024 | 358602 | 0.380 |
Why?
|
ACTH Syndrome, Ectopic | 2 | 2008 | 29 | 0.380 |
Why?
|
Heart Valves | 2 | 2010 | 285 | 0.380 |
Why?
|
Young Adult | 35 | 2024 | 58477 | 0.360 |
Why?
|
Adrenalectomy | 5 | 2017 | 348 | 0.360 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2018 | 1522 | 0.360 |
Why?
|
Consensus | 7 | 2021 | 3091 | 0.350 |
Why?
|
Databases, Factual | 9 | 2015 | 8001 | 0.340 |
Why?
|
Dose-Response Relationship, Drug | 9 | 2020 | 10825 | 0.320 |
Why?
|
Amenorrhea | 7 | 1999 | 480 | 0.320 |
Why?
|
Societies, Scientific | 1 | 2009 | 221 | 0.310 |
Why?
|
Gonadal Steroid Hormones | 1 | 2011 | 700 | 0.280 |
Why?
|
Delayed-Action Preparations | 8 | 2018 | 961 | 0.280 |
Why?
|
Metabolism, Inborn Errors | 2 | 2007 | 284 | 0.270 |
Why?
|
Drug Administration Schedule | 8 | 2018 | 4893 | 0.270 |
Why?
|
Double-Blind Method | 16 | 2020 | 12383 | 0.260 |
Why?
|
Pituitary Diseases | 5 | 2016 | 135 | 0.260 |
Why?
|
Lumbar Vertebrae | 2 | 2013 | 1851 | 0.260 |
Why?
|
Aged | 48 | 2020 | 168615 | 0.250 |
Why?
|
Craniopharyngioma | 3 | 2017 | 277 | 0.240 |
Why?
|
Dexamethasone | 4 | 2009 | 1927 | 0.230 |
Why?
|
Remission Induction | 6 | 2015 | 2388 | 0.230 |
Why?
|
Pituitary Hormones, Anterior | 2 | 2022 | 56 | 0.230 |
Why?
|
Tryptophan | 2 | 2018 | 480 | 0.230 |
Why?
|
Etomidate | 2 | 2019 | 185 | 0.230 |
Why?
|
Retrospective Studies | 30 | 2021 | 80125 | 0.220 |
Why?
|
Neurosurgical Procedures | 4 | 2020 | 2052 | 0.220 |
Why?
|
Growth Hormone-Releasing Hormone | 4 | 2013 | 128 | 0.210 |
Why?
|
Insulin | 8 | 2022 | 6589 | 0.210 |
Why?
|
Bone Diseases, Metabolic | 5 | 1995 | 409 | 0.210 |
Why?
|
Reference Values | 7 | 2016 | 4914 | 0.210 |
Why?
|
Adipose Tissue | 5 | 2011 | 3291 | 0.200 |
Why?
|
Adolescent | 36 | 2023 | 87551 | 0.200 |
Why?
|
Clinical Laboratory Techniques | 2 | 2020 | 749 | 0.200 |
Why?
|
Heart Valve Diseases | 1 | 2010 | 1048 | 0.200 |
Why?
|
Age of Onset | 6 | 2018 | 3301 | 0.200 |
Why?
|
Hyperlipidemias | 2 | 2017 | 782 | 0.200 |
Why?
|
Octreotide | 5 | 2020 | 152 | 0.200 |
Why?
|
Leydig Cell Tumor | 1 | 2001 | 28 | 0.190 |
Why?
|
Mixed Function Oxygenases | 1 | 2022 | 265 | 0.190 |
Why?
|
Bone and Bones | 5 | 2009 | 2558 | 0.190 |
Why?
|
Absorptiometry, Photon | 7 | 2017 | 1725 | 0.190 |
Why?
|
Follow-Up Studies | 12 | 2020 | 39213 | 0.180 |
Why?
|
Cosyntropin | 2 | 2021 | 34 | 0.180 |
Why?
|
Blood Glucose | 11 | 2016 | 6366 | 0.180 |
Why?
|
Gynecomastia | 1 | 2001 | 87 | 0.180 |
Why?
|
Prospective Studies | 12 | 2024 | 54190 | 0.180 |
Why?
|
Body Mass Index | 10 | 2019 | 12871 | 0.180 |
Why?
|
Testosterone | 6 | 2022 | 2468 | 0.180 |
Why?
|
Internationality | 2 | 2018 | 1003 | 0.180 |
Why?
|
Body Height | 4 | 2018 | 1569 | 0.170 |
Why?
|
Insulin Resistance | 3 | 2012 | 3959 | 0.170 |
Why?
|
Glucocorticoids | 2 | 2020 | 2142 | 0.170 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2021 | 255 | 0.160 |
Why?
|
Hypoglycemic Agents | 4 | 2017 | 3153 | 0.160 |
Why?
|
Postoperative Care | 2 | 2005 | 1476 | 0.160 |
Why?
|
Pituitary Function Tests | 1 | 2018 | 24 | 0.160 |
Why?
|
Practice Guidelines as Topic | 5 | 2021 | 7460 | 0.160 |
Why?
|
Nelson Syndrome | 2 | 2008 | 20 | 0.150 |
Why?
|
Central Nervous System Cysts | 2 | 2016 | 56 | 0.150 |
Why?
|
Technology, Pharmaceutical | 1 | 2018 | 84 | 0.150 |
Why?
|
Waist Circumference | 2 | 2019 | 921 | 0.150 |
Why?
|
14-alpha Demethylase Inhibitors | 1 | 2017 | 4 | 0.150 |
Why?
|
Pituitary Irradiation | 1 | 2017 | 14 | 0.150 |
Why?
|
Medical Oncology | 1 | 2009 | 2309 | 0.150 |
Why?
|
Striae Distensae | 1 | 2017 | 7 | 0.150 |
Why?
|
Indoles | 2 | 2018 | 1828 | 0.150 |
Why?
|
Pregnancy Outcome | 2 | 2021 | 2901 | 0.150 |
Why?
|
Hypothalamic Diseases | 4 | 2012 | 134 | 0.150 |
Why?
|
Stimulation, Chemical | 2 | 2011 | 306 | 0.150 |
Why?
|
Hirsutism | 1 | 2017 | 68 | 0.140 |
Why?
|
Europe | 3 | 2019 | 3427 | 0.140 |
Why?
|
Sensitivity and Specificity | 7 | 2018 | 14648 | 0.140 |
Why?
|
Diagnostic Errors | 1 | 2004 | 1266 | 0.140 |
Why?
|
Alanine Transaminase | 1 | 2019 | 607 | 0.140 |
Why?
|
Child | 19 | 2023 | 79604 | 0.140 |
Why?
|
Age Factors | 7 | 2020 | 18391 | 0.130 |
Why?
|
Body Weight | 5 | 2016 | 4606 | 0.130 |
Why?
|
Adrenal Hyperplasia, Congenital | 1 | 2016 | 102 | 0.130 |
Why?
|
Hypertension | 5 | 2020 | 8582 | 0.130 |
Why?
|
Hypothalamus | 2 | 1991 | 998 | 0.130 |
Why?
|
Injections | 1 | 2018 | 828 | 0.130 |
Why?
|
Electric Impedance | 1 | 2019 | 749 | 0.120 |
Why?
|
Substance Withdrawal Syndrome | 1 | 2000 | 623 | 0.120 |
Why?
|
Long QT Syndrome | 1 | 2019 | 465 | 0.120 |
Why?
|
Testicular Neoplasms | 1 | 2001 | 800 | 0.120 |
Why?
|
Radius | 2 | 2017 | 435 | 0.120 |
Why?
|
Sex Characteristics | 5 | 2011 | 2627 | 0.120 |
Why?
|
Cardiovascular Diseases | 11 | 2020 | 15726 | 0.120 |
Why?
|
Pituitary Apoplexy | 1 | 2014 | 29 | 0.120 |
Why?
|
Cholesterol | 3 | 2014 | 2922 | 0.120 |
Why?
|
Muscular Atrophy | 1 | 2017 | 331 | 0.120 |
Why?
|
Muscle Weakness | 1 | 2017 | 413 | 0.120 |
Why?
|
Thiazolidinediones | 1 | 2017 | 465 | 0.120 |
Why?
|
Obesity, Abdominal | 1 | 2017 | 375 | 0.110 |
Why?
|
Thyrotropin | 3 | 2014 | 832 | 0.110 |
Why?
|
Time Factors | 13 | 2020 | 40083 | 0.110 |
Why?
|
Radiotherapy | 1 | 2020 | 1503 | 0.110 |
Why?
|
Androgens | 3 | 2007 | 1287 | 0.110 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2017 | 375 | 0.110 |
Why?
|
Hospitals, General | 1 | 1997 | 795 | 0.110 |
Why?
|
Glucose Tolerance Test | 2 | 2017 | 1174 | 0.100 |
Why?
|
United States | 8 | 2022 | 72238 | 0.100 |
Why?
|
Diagnostic Tests, Routine | 1 | 2018 | 784 | 0.100 |
Why?
|
Patient Care Team | 2 | 2021 | 2509 | 0.100 |
Why?
|
Tetrahydronaphthalenes | 1 | 2012 | 86 | 0.100 |
Why?
|
Sex Factors | 4 | 2013 | 10515 | 0.100 |
Why?
|
Urinalysis | 1 | 2013 | 368 | 0.100 |
Why?
|
Impulsive Behavior | 1 | 2014 | 346 | 0.100 |
Why?
|
Femur Neck | 1 | 2013 | 311 | 0.100 |
Why?
|
Tumor Burden | 1 | 2017 | 1886 | 0.090 |
Why?
|
Ghrelin | 1 | 2013 | 252 | 0.090 |
Why?
|
Ambulatory Care Facilities | 1 | 1997 | 924 | 0.090 |
Why?
|
Cysts | 1 | 2016 | 684 | 0.090 |
Why?
|
Case-Control Studies | 5 | 2020 | 21992 | 0.090 |
Why?
|
Comorbidity | 4 | 2020 | 10550 | 0.090 |
Why?
|
Sella Turcica | 1 | 2010 | 118 | 0.090 |
Why?
|
Pregnancy | 6 | 2023 | 29650 | 0.090 |
Why?
|
Meningioma | 2 | 2017 | 1217 | 0.090 |
Why?
|
Cross-Sectional Studies | 8 | 2018 | 25853 | 0.090 |
Why?
|
Adrenal Gland Neoplasms | 3 | 2015 | 734 | 0.090 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2015 | 1785 | 0.080 |
Why?
|
Adipokines | 1 | 2011 | 311 | 0.080 |
Why?
|
Neurology | 1 | 1997 | 775 | 0.080 |
Why?
|
Administration, Oral | 4 | 2020 | 4037 | 0.080 |
Why?
|
Child Welfare | 1 | 2013 | 516 | 0.080 |
Why?
|
Perception | 1 | 2015 | 1189 | 0.080 |
Why?
|
Insurance Coverage | 1 | 2000 | 1939 | 0.080 |
Why?
|
Diagnosis, Differential | 6 | 2010 | 12963 | 0.080 |
Why?
|
Neuroblastoma | 1 | 2017 | 1252 | 0.080 |
Why?
|
Pharmacoepidemiology | 1 | 2012 | 346 | 0.080 |
Why?
|
Nose | 1 | 2012 | 515 | 0.080 |
Why?
|
Mortality | 1 | 2020 | 2913 | 0.080 |
Why?
|
Hypophysectomy | 1 | 2008 | 114 | 0.080 |
Why?
|
Needs Assessment | 1 | 2014 | 1137 | 0.080 |
Why?
|
Knowledge | 1 | 2009 | 176 | 0.080 |
Why?
|
Prognosis | 5 | 2020 | 29559 | 0.080 |
Why?
|
Early Diagnosis | 1 | 2013 | 1180 | 0.080 |
Why?
|
Estrogens | 4 | 2022 | 1520 | 0.080 |
Why?
|
ROC Curve | 3 | 2020 | 3569 | 0.070 |
Why?
|
Statistics, Nonparametric | 2 | 2012 | 2852 | 0.070 |
Why?
|
Meningeal Neoplasms | 1 | 2017 | 1245 | 0.070 |
Why?
|
Professional Practice | 1 | 2009 | 313 | 0.070 |
Why?
|
Cross-Over Studies | 4 | 2018 | 2058 | 0.070 |
Why?
|
Drug Therapy, Combination | 1 | 2018 | 6490 | 0.070 |
Why?
|
Blood Pressure | 3 | 2013 | 8520 | 0.070 |
Why?
|
Aged, 80 and over | 12 | 2018 | 58864 | 0.070 |
Why?
|
Endocrine System Diseases | 2 | 2002 | 251 | 0.070 |
Why?
|
Bromocriptine | 3 | 2007 | 93 | 0.070 |
Why?
|
Single-Blind Method | 4 | 2012 | 1574 | 0.070 |
Why?
|
Anorexia Nervosa | 3 | 1995 | 1357 | 0.070 |
Why?
|
Steroid Metabolism, Inborn Errors | 1 | 2005 | 5 | 0.070 |
Why?
|
Recurrence | 7 | 2015 | 8465 | 0.070 |
Why?
|
Homeostasis | 1 | 2016 | 3301 | 0.060 |
Why?
|
Spine | 3 | 2011 | 1111 | 0.060 |
Why?
|
Bariatric Surgery | 1 | 2015 | 993 | 0.060 |
Why?
|
Quinazolines | 1 | 2012 | 1362 | 0.060 |
Why?
|
Analgesics, Opioid | 1 | 2021 | 3759 | 0.060 |
Why?
|
Triglycerides | 1 | 2013 | 2475 | 0.060 |
Why?
|
Injections, Subcutaneous | 2 | 2022 | 679 | 0.060 |
Why?
|
Drug Interactions | 1 | 2009 | 1422 | 0.060 |
Why?
|
Differential Threshold | 1 | 2004 | 80 | 0.060 |
Why?
|
Obesity, Morbid | 1 | 2015 | 1277 | 0.060 |
Why?
|
Levodopa | 2 | 2002 | 217 | 0.060 |
Why?
|
Deficiency Diseases | 1 | 2004 | 74 | 0.060 |
Why?
|
Estradiol | 3 | 2001 | 1931 | 0.060 |
Why?
|
Longitudinal Studies | 3 | 2010 | 14439 | 0.060 |
Why?
|
Analysis of Variance | 2 | 2011 | 6239 | 0.060 |
Why?
|
Risk Factors | 12 | 2020 | 74167 | 0.060 |
Why?
|
Pituitary Hormones | 2 | 2021 | 182 | 0.060 |
Why?
|
Societies, Medical | 1 | 2015 | 3890 | 0.060 |
Why?
|
Overweight | 1 | 2014 | 2420 | 0.050 |
Why?
|
False Negative Reactions | 1 | 2004 | 574 | 0.050 |
Why?
|
International Cooperation | 1 | 2009 | 1435 | 0.050 |
Why?
|
Oligopeptides | 1 | 2008 | 1186 | 0.050 |
Why?
|
Feasibility Studies | 1 | 2013 | 5192 | 0.050 |
Why?
|
Intra-Abdominal Fat | 1 | 2008 | 607 | 0.050 |
Why?
|
Chemistry, Pharmaceutical | 2 | 2015 | 277 | 0.050 |
Why?
|
Osteoporosis | 2 | 2009 | 1600 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3088 | 0.050 |
Why?
|
Phenol | 1 | 2022 | 44 | 0.050 |
Why?
|
Models, Theoretical | 1 | 2014 | 3556 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3208 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2022 | 9271 | 0.050 |
Why?
|
Glioma | 1 | 2017 | 3414 | 0.050 |
Why?
|
Radiography | 1 | 2013 | 6964 | 0.050 |
Why?
|
Logistic Models | 1 | 2016 | 13309 | 0.050 |
Why?
|
Mannitol | 1 | 2022 | 180 | 0.050 |
Why?
|
Homocystine | 1 | 2001 | 21 | 0.050 |
Why?
|
Anxiety | 1 | 2016 | 4527 | 0.050 |
Why?
|
Histidine | 1 | 2022 | 312 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2020 | 6530 | 0.050 |
Why?
|
Hepatitis C Antibodies | 1 | 2001 | 145 | 0.050 |
Why?
|
Diabetes Mellitus | 2 | 2016 | 5875 | 0.050 |
Why?
|
Child, Preschool | 5 | 2018 | 41932 | 0.050 |
Why?
|
Reproducibility of Results | 3 | 2019 | 20027 | 0.050 |
Why?
|
Hospitalization | 2 | 2021 | 10732 | 0.050 |
Why?
|
Postoperative Period | 2 | 2015 | 1823 | 0.040 |
Why?
|
Heroin Dependence | 1 | 2001 | 172 | 0.040 |
Why?
|
Sphenoid Bone | 2 | 2014 | 177 | 0.040 |
Why?
|
Galactorrhea | 1 | 1999 | 22 | 0.040 |
Why?
|
Lipids | 6 | 2012 | 3337 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 8 | 2016 | 36164 | 0.040 |
Why?
|
Receptors, Somatostatin | 1 | 2020 | 135 | 0.040 |
Why?
|
Severity of Illness Index | 3 | 2013 | 15815 | 0.040 |
Why?
|
Orchiectomy | 1 | 2001 | 470 | 0.040 |
Why?
|
Placebos | 4 | 2008 | 1672 | 0.040 |
Why?
|
Fractures, Bone | 1 | 2011 | 2035 | 0.040 |
Why?
|
Abdomen | 1 | 2004 | 1120 | 0.040 |
Why?
|
Testis | 1 | 2001 | 794 | 0.040 |
Why?
|
Homocysteine | 1 | 2001 | 640 | 0.040 |
Why?
|
Time | 1 | 2019 | 545 | 0.040 |
Why?
|
Animals | 4 | 2020 | 167531 | 0.040 |
Why?
|
Endocrine Glands | 1 | 1997 | 101 | 0.040 |
Why?
|
Fasting | 2 | 2019 | 1603 | 0.040 |
Why?
|
HIV Wasting Syndrome | 1 | 1997 | 97 | 0.040 |
Why?
|
Health Status | 1 | 2010 | 4079 | 0.030 |
Why?
|
Depression | 1 | 2016 | 8026 | 0.030 |
Why?
|
Evidence-Based Medicine | 3 | 2015 | 3694 | 0.030 |
Why?
|
Gonads | 1 | 1996 | 109 | 0.030 |
Why?
|
Drug Combinations | 1 | 2002 | 2021 | 0.030 |
Why?
|
Antineoplastic Agents | 2 | 2017 | 13625 | 0.030 |
Why?
|
Medical History Taking | 1 | 1999 | 773 | 0.030 |
Why?
|
Poisson Distribution | 1 | 2017 | 507 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 2017 | 8950 | 0.030 |
Why?
|
Lipoproteins | 2 | 2012 | 883 | 0.030 |
Why?
|
Metabolic Diseases | 1 | 2002 | 686 | 0.030 |
Why?
|
Oligodendroglioma | 1 | 2017 | 279 | 0.030 |
Why?
|
Meta-Analysis as Topic | 1 | 2020 | 1374 | 0.030 |
Why?
|
Glucose | 2 | 2022 | 4362 | 0.030 |
Why?
|
Managed Care Programs | 1 | 2000 | 938 | 0.030 |
Why?
|
Blotting, Southern | 2 | 1992 | 780 | 0.030 |
Why?
|
Obesity | 2 | 2014 | 12896 | 0.030 |
Why?
|
Regression Analysis | 3 | 2017 | 6358 | 0.030 |
Why?
|
Progesterone | 1 | 1999 | 743 | 0.030 |
Why?
|
Polymorphism, Restriction Fragment Length | 2 | 1992 | 760 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2014 | 165 | 0.030 |
Why?
|
Follicle Stimulating Hormone | 3 | 1995 | 724 | 0.030 |
Why?
|
Immune System Diseases | 1 | 2016 | 258 | 0.030 |
Why?
|
Infertility, Female | 1 | 1999 | 762 | 0.030 |
Why?
|
Luteinizing Hormone | 3 | 1995 | 820 | 0.030 |
Why?
|
Ultrasonography | 2 | 2009 | 5954 | 0.030 |
Why?
|
Gonadotropin-Releasing Hormone | 2 | 1990 | 1155 | 0.030 |
Why?
|
Cohort Studies | 2 | 2020 | 41266 | 0.030 |
Why?
|
Safety | 1 | 2017 | 1149 | 0.030 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2016 | 351 | 0.030 |
Why?
|
Education | 1 | 2015 | 534 | 0.030 |
Why?
|
Astrocytoma | 1 | 2017 | 775 | 0.030 |
Why?
|
Diagnostic Imaging | 2 | 2023 | 3526 | 0.030 |
Why?
|
Glasgow Coma Scale | 1 | 2014 | 579 | 0.030 |
Why?
|
Clone Cells | 2 | 1992 | 1657 | 0.020 |
Why?
|
Massachusetts | 2 | 2012 | 8788 | 0.020 |
Why?
|
Live Birth | 1 | 2015 | 513 | 0.020 |
Why?
|
Osmolar Concentration | 1 | 1992 | 662 | 0.020 |
Why?
|
Survivors | 1 | 2022 | 2355 | 0.020 |
Why?
|
Puberty, Delayed | 1 | 1992 | 121 | 0.020 |
Why?
|
Radiotherapy, Conformal | 1 | 2014 | 549 | 0.020 |
Why?
|
Lipoproteins, LDL | 1 | 2014 | 641 | 0.020 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2015 | 496 | 0.020 |
Why?
|
Aging | 3 | 2002 | 8633 | 0.020 |
Why?
|
Liver Function Tests | 1 | 2012 | 524 | 0.020 |
Why?
|
Aftercare | 1 | 2016 | 919 | 0.020 |
Why?
|
Musculoskeletal Diseases | 1 | 2016 | 594 | 0.020 |
Why?
|
Aminoquinolines | 1 | 1990 | 108 | 0.020 |
Why?
|
Patient Care Planning | 1 | 2015 | 907 | 0.020 |
Why?
|
Urea | 1 | 2012 | 441 | 0.020 |
Why?
|
C-Reactive Protein | 3 | 2010 | 3822 | 0.020 |
Why?
|
Treatment Failure | 1 | 2015 | 2641 | 0.020 |
Why?
|
Visual Fields | 1 | 1996 | 1053 | 0.020 |
Why?
|
Survival Rate | 2 | 2020 | 12793 | 0.020 |
Why?
|
Dopamine Agents | 1 | 1990 | 189 | 0.020 |
Why?
|
Doping in Sports | 1 | 2009 | 62 | 0.020 |
Why?
|
Cause of Death | 1 | 2020 | 3719 | 0.020 |
Why?
|
X Chromosome | 1 | 1992 | 815 | 0.020 |
Why?
|
Research | 1 | 1997 | 1972 | 0.020 |
Why?
|
Somatomedins | 1 | 1989 | 178 | 0.020 |
Why?
|
Gallbladder | 1 | 2009 | 306 | 0.020 |
Why?
|
Postoperative Complications | 3 | 2008 | 15662 | 0.020 |
Why?
|
Minerals | 1 | 1989 | 282 | 0.020 |
Why?
|
Glucose Intolerance | 1 | 2012 | 579 | 0.020 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 2 | 2002 | 415 | 0.020 |
Why?
|
Ependymoma | 1 | 2010 | 319 | 0.020 |
Why?
|
Anthropometry | 2 | 2004 | 1344 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2014 | 2895 | 0.020 |
Why?
|
Growth Hormone-Secreting Pituitary Adenoma | 1 | 2007 | 49 | 0.020 |
Why?
|
Calcitriol | 1 | 1989 | 295 | 0.020 |
Why?
|
Area Under Curve | 1 | 2011 | 1634 | 0.020 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2012 | 450 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2010 | 597 | 0.020 |
Why?
|
Birth Weight | 1 | 2015 | 2085 | 0.020 |
Why?
|
Health Services Research | 1 | 2014 | 1809 | 0.020 |
Why?
|
Quinolines | 1 | 2012 | 758 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 1997 | 1645 | 0.020 |
Why?
|
Gestational Age | 1 | 2015 | 3558 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 4 | 2005 | 20461 | 0.020 |
Why?
|
Cognition | 2 | 2006 | 6939 | 0.020 |
Why?
|
Menstrual Cycle | 3 | 1999 | 534 | 0.020 |
Why?
|
Bone Resorption | 1 | 1989 | 719 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2013 | 1783 | 0.020 |
Why?
|
Weight Gain | 1 | 2015 | 2345 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2020 | 12526 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 1997 | 2352 | 0.020 |
Why?
|
Metabolome | 1 | 2011 | 974 | 0.020 |
Why?
|
Inpatients | 1 | 2016 | 2580 | 0.020 |
Why?
|
Psychometrics | 1 | 2014 | 3046 | 0.010 |
Why?
|
Smoking | 1 | 2001 | 9066 | 0.010 |
Why?
|
Inflammation Mediators | 1 | 2012 | 1882 | 0.010 |
Why?
|
Infant | 2 | 2018 | 35940 | 0.010 |
Why?
|
Leptin | 1 | 2011 | 1589 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 1992 | 6070 | 0.010 |
Why?
|
Mental Disorders | 2 | 2016 | 6788 | 0.010 |
Why?
|
Clinical Chemistry Tests | 1 | 2003 | 58 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2009 | 1395 | 0.010 |
Why?
|
Self Report | 1 | 2014 | 3699 | 0.010 |
Why?
|
Prevalence | 2 | 2014 | 15639 | 0.010 |
Why?
|
Stress, Physiological | 1 | 1990 | 1395 | 0.010 |
Why?
|
Protons | 1 | 2007 | 1114 | 0.010 |
Why?
|
Antihypertensive Agents | 1 | 2012 | 2062 | 0.010 |
Why?
|
Glioblastoma | 1 | 2017 | 3481 | 0.010 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2012 | 6016 | 0.010 |
Why?
|
Predictive Value of Tests | 2 | 2012 | 15262 | 0.010 |
Why?
|
Physical Endurance | 1 | 2004 | 363 | 0.010 |
Why?
|
Pregnancy Complications | 1 | 2015 | 2938 | 0.010 |
Why?
|
Menopause | 1 | 1989 | 1640 | 0.010 |
Why?
|
Pheochromocytoma | 1 | 2003 | 328 | 0.010 |
Why?
|
Pilot Projects | 1 | 2014 | 8530 | 0.010 |
Why?
|
Biopsy | 1 | 1992 | 6770 | 0.010 |
Why?
|
Inflammation | 1 | 2000 | 10746 | 0.010 |
Why?
|
Pediatrics | 1 | 2015 | 3584 | 0.010 |
Why?
|
Serum Amyloid A Protein | 1 | 2000 | 126 | 0.010 |
Why?
|
Arousal | 1 | 2006 | 1157 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8604 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 6165 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2016 | 8050 | 0.010 |
Why?
|
Hypogonadism | 1 | 2006 | 800 | 0.010 |
Why?
|
Calcitonin | 1 | 1980 | 330 | 0.010 |
Why?
|
Administration, Intravaginal | 1 | 1999 | 149 | 0.010 |
Why?
|
Matched-Pair Analysis | 1 | 1999 | 284 | 0.010 |
Why?
|
Lipid Metabolism | 1 | 2007 | 1902 | 0.010 |
Why?
|
Incidence | 1 | 2017 | 21344 | 0.010 |
Why?
|
Weight Loss | 1 | 1990 | 2673 | 0.010 |
Why?
|
Primary Ovarian Insufficiency | 1 | 1999 | 106 | 0.010 |
Why?
|
Child Development | 1 | 2010 | 2274 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 1993 | 5793 | 0.010 |
Why?
|
Thyroid Hormones | 1 | 2001 | 403 | 0.010 |
Why?
|
Affect | 1 | 2006 | 1479 | 0.010 |
Why?
|
Vitamin B 12 | 1 | 2001 | 522 | 0.010 |
Why?
|
Nutrition Assessment | 1 | 2001 | 725 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2003 | 1631 | 0.010 |
Why?
|
Gels | 1 | 1999 | 419 | 0.010 |
Why?
|
Kinetics | 2 | 2002 | 6373 | 0.010 |
Why?
|
Reoperation | 1 | 2008 | 4286 | 0.010 |
Why?
|
Emotions | 1 | 2009 | 2731 | 0.010 |
Why?
|
Echocardiography | 1 | 2009 | 4970 | 0.010 |
Why?
|
Dehydroepiandrosterone Sulfate | 1 | 1997 | 240 | 0.010 |
Why?
|
Carrier Proteins | 2 | 2002 | 4938 | 0.010 |
Why?
|
Sexual Behavior | 1 | 2006 | 2086 | 0.010 |
Why?
|
Endometrium | 1 | 1999 | 404 | 0.010 |
Why?
|
Insulin-Like Growth Factor Binding Protein 2 | 1 | 1996 | 68 | 0.010 |
Why?
|
Muscle, Skeletal | 2 | 2004 | 4922 | 0.010 |
Why?
|
Glycoproteins | 1 | 2002 | 2202 | 0.010 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 1997 | 545 | 0.010 |
Why?
|
Folic Acid | 1 | 2001 | 1303 | 0.010 |
Why?
|
Seizures | 1 | 1987 | 2908 | 0.010 |
Why?
|
Morbidity | 1 | 1998 | 1763 | 0.010 |
Why?
|
Statistics as Topic | 1 | 1999 | 2364 | 0.010 |
Why?
|
Ion Exchange | 1 | 1972 | 16 | 0.010 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 1993 | 283 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2009 | 10329 | 0.010 |
Why?
|
Muscles | 1 | 1997 | 1582 | 0.010 |
Why?
|
Risk Assessment | 1 | 2013 | 24049 | 0.010 |
Why?
|
Amphetamine | 1 | 1972 | 224 | 0.010 |
Why?
|
Phosphoglycerate Kinase | 1 | 1990 | 67 | 0.010 |
Why?
|
Hypoxanthine Phosphoribosyltransferase | 1 | 1990 | 69 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2000 | 3201 | 0.010 |
Why?
|
Narcotics | 1 | 1972 | 336 | 0.010 |
Why?
|
Libido | 1 | 1990 | 119 | 0.010 |
Why?
|
Energy Intake | 1 | 1997 | 2126 | 0.010 |
Why?
|
Dosage Compensation, Genetic | 1 | 1990 | 207 | 0.010 |
Why?
|
Carcinoma | 1 | 1980 | 2335 | 0.010 |
Why?
|
Disabled Persons | 1 | 1998 | 1226 | 0.000 |
Why?
|
Nutritional Status | 1 | 1997 | 1604 | 0.000 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2012 | 12270 | 0.000 |
Why?
|
Methylation | 1 | 1990 | 1080 | 0.000 |
Why?
|
Thyroid Neoplasms | 1 | 1980 | 2329 | 0.000 |
Why?
|
Combined Modality Therapy | 1 | 1998 | 8548 | 0.000 |
Why?
|
Erectile Dysfunction | 1 | 1990 | 452 | 0.000 |
Why?
|
Menarche | 1 | 1989 | 529 | 0.000 |
Why?
|
Energy Metabolism | 1 | 1997 | 2869 | 0.000 |
Why?
|
Hypnotics and Sedatives | 1 | 1972 | 1177 | 0.000 |
Why?
|
Chronic Disease | 1 | 1998 | 9245 | 0.000 |
Why?
|
Pentagastrin | 1 | 1980 | 17 | 0.000 |
Why?
|
Neoplasms | 1 | 2010 | 22023 | 0.000 |
Why?
|
Exercise | 1 | 1996 | 5774 | 0.000 |
Why?
|
Substance-Related Disorders | 1 | 1972 | 4358 | 0.000 |
Why?
|
Chromatography, Thin Layer | 1 | 1972 | 214 | 0.000 |
Why?
|
Methods | 1 | 1972 | 1074 | 0.000 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1972 | 2511 | 0.000 |
Why?
|